BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...
Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a ...
Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...
And not only were we fortunate enough to score TWO exclusive clips from this highly anticipated hour (as well as Scott Wolf’s ...
Biopharma stocks may rally in 2026 as M&A heats up and drug pricing uncertainty fades—see why UBS expects big pharma to buy ...
After a whirlwind of conference news Monday, we're doing it all over again with Day 2 of the J.P. Morgan Healthcare ...
24/7 Wall St. on MSN
Fed Governor Wants Huge Rate Cuts This Year: 5 High-Yield Dividend Stocks to Buy Today
These five high-yield dividend stocks with solid upside potential and Buy ratings make sense for growth and income investors ...
In this episode, Caroline Michie discusses key data from ASCENT-3, TROPION2, and PLANeT, and how these findings translate ...
The University of Pennsylvania, biotech firm BioNTech, and Osage University Partners, a venture capital firm in Bala Cynwyd, ...
Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive ...
Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback